Bayer AG has posted a strong set of financials for the first quarter and while its pharmaceuticals division's sales slightly missed analyst forecasts, the German major is pleased with the performance of its new products, especially the prostate cancer drug Nubeqa.
D-Day Approaches For Bayer’s Asundexian Phase III Plans
Factor XIa Inhibitor Impressive So Far
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.
